Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Department of Immunology, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Archives of Virology (Impact Factor: 2.39). 07/2009; 154(7):1093-9. DOI: 10.1007/s00705-009-0409-6
Source: PubMed


SARS-CoV infection of human results in antigen-specific cellular and humoral immune responses. However, it is critical to determine whether SARS-CoV-specific memory T cells can persist for long periods of time. In this study, we analyzed the cellular immune response from 21 SARS-recovered individuals who had been diagnosed with SARS in 2003 by using ELISA, CBA, ELISpot and multiparameter flow cytometry assays. Our results demonstrated that low levels of specific memory T cell responses to SARS-CoV S, M, E and N peptides were detected in a proportion of SARS-recovered patients, and IFN-gamma was the predominant cytokine produced by T cells after stimulation with peptides. Cytometry analysis indicated that the majority of memory CD8(+) T cells produced IFN-gamma, whereas memory CD4(+) T cells produced IFN-gamma, IL-2 or TNF-alpha. These results might provide valuable information on the cellular immune response in recovered SARS-CoV patients for the rational design of vaccines against SARS-CoV infection.

Full-text preview

Available from:
  • Source
    • "Using peptides in the four SARS-CoV structural proteins, an analysis of the memory T cell response in recovered SARS patients four years post-infection revealed that both CD4+ and CD8+ T cells produced IFNγ.43 In support of Li et al.'s study,34 Fan et al. also found that CD4+ memory T cells produce IL-2, TNFα and IFNγ, with the exception of one patient.43 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The severe acute respiratory syndrome (SARS) epidemic started in late 2002 and swiftly spread across 5 continents with a mortality rate of around 10%. Although the epidemic was eventually controlled through the implementation of strict quarantine measures, there continues a need to investigate the SARS coronavirus (SARS-CoV) and develop interventions should it re-emerge. Numerous studies have shown that neutralizing antibodies against the virus can be found in patients infected with SARS-CoV within days upon the onset of illness and lasting up to several months. In contrast, there is little data on the kinetics of T cell responses during SARS-CoV infection and little is known about their role in the recovery process. However, recent studies in mice suggest the importance of T cells in viral clearance during SARS-CoV infection. Moreover, a growing number of studies have investigated the memory T cell responses in recovered SARS patients. This review covers the available literature on the emerging importance of T cell responses in SARS-CoV infection, particularly on the mapping of cytotoxic T lymphocyte (CTL) epitopes, longevity, polyfunctionality and human leukocyte antigen (HLA) association as well as their potential implications on treatment and vaccine development.
    Emerging Microbes and Infections 09/2012; 1(9). DOI:10.1038/emi.2012.26 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The severe acute respiratory syndrome (SARS) is a newly identified infectious disease caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs. The risk of SARS reemergence in humans remains high due to the large animal reservoirs of SARS-CoV-like coronavirus and the genome instability of RNA coronaviruses. An epidemic in 2003 affected more than 8,000 patients in 29 countries, with 10% mortality. SARS infection is transmitted by air droplets. Clinical and laboratory manifestations include fever, chills, rigor, myalgia, malaise, diarrhea, cough, dyspnoea, pneumonia, lymphopenia, neutrophilia, thrombocytopenia, and elevated serum lactate dehydrogenase, alanine aminotransferase, and creatine kinase activities. Health care workers are a high-risk group, and advanced age is strongly associated with disease severity. Treatment has been empirical, and there is no licensed SARS vaccine for humans so far. However, presence of long-lived neutralizing antibodies and memory T- and B-lymphocytes in convalescent SARS patients raises hope for active immunization. Furthermore, results from preclinical SARS vaccines expressing spike protein to elicit neutralizing antibodies and cellular responses that are protective in mouse and nonhuman primate models are encouraging. Very little is known of the early events in viral clearance and the onset of innate and inflammatory responses during the SARS infection. Regulation of the innate immune response is associated with the development of adaptive immunity and disease severity in SARS infection. Notably, SARS-CoV has evolved evasive strategies to suppress antiviral type I interferon responses in infected cells. In addition, inflammatory responses are characterized by upregulation of proinflammatory cytokines/chemokines such as IL-6, IP-10, and MCP-1 in tissues and serum, and massive infiltrations of inflammatory cells such as macrophages in infected tissues. Due to the lack of animal models that mimic the clinical manifestations of human SARS infection for mechanistic study and vaccine evaluation, development of a safe prophylactic SARS vaccine for human use remains a huge challenge. This chapter is written to summarize and highlight the latest clinical, serological, and immunological parameters relevant to the pathogenesis and protective immunity of SARS infection in humans.
    12/2009: pages 259-278;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunological memory is the basis for vaccination. Currently, the longitudinal profiles of antibody responses in recovered severe acute respiratory syndrome (SARS) patients have not been fully characterized. In this study we sequentially followed up 19 recovered SARS patients over a 3-y period in order to characterize the dynamic changes in antibody responses against viral components in detail. In addition, 4 blood samples were obtained at month 60. We found that immunoglobulin G (IgG) antibodies and their neutralizing activities decreased throughout the entire phase of the study. For IgG antibodies in the 3rd y, the positive rate of whole-virus-specific antibodies was 42%, which was tested with commercial kits at 1/10 dilution of the sera. In comparison, the positive rate of spike (S) protein-specific antibodies was 100%, which was tested by spike protein-based ELISA at 1/100 dilution; 4 samples at month 60 were included. The average optical density (OD) reading of nucleocapsid (N) protein-specific antibodies fell dramatically between month 3 and month 12, and it decreased gradually at low levels that were a little higher than the cut-off value from month 12. For neutralizing antibodies, neutralizing activity was detectable in 89% of recovered patients in the 3rd y. S protein-specific IgG levels (r = 0.717) correlated better with neutralizing activity than SARS coronavirus-specific IgG levels (r = 0.571). These systematic findings provide valuable information on natural humoral memory responses, and the data will be helpful for understanding the pathogenesis of SARS coronavirus infection and for the rational design of vaccines.
    Scandinavian Journal of Infectious Diseases 03/2011; 43(6-7):515-21. DOI:10.3109/00365548.2011.560184 · 1.50 Impact Factor
Show more